Mesar (Olmesartan Medoxomil)

• Olmesartan medoxomil belongs to the angiotensin II receptor blocker class and is used to manage high‑blood‑pressure disorders.
• Hypertension: lowers systolic and diastolic blood pressure, helping to achieve guideline‑recommended targets.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone secretion, leading to reduced peripheral resistance, decreased sodium‑water retention, and ultimately a fall in arterial blood pressure.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pressure or throbbing pain.
• Fatigue: feeling unusually tired or weak.
• Abdominal discomfort: mild stomach pain or nausea.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or throat that may compromise breathing.
• Hyperkalemia: elevated blood potassium levels, potentially causing cardiac arrhythmia.
• Acute kidney injury: sudden decline in renal function, indicated by reduced urine output or rising creatinine.

Before initiating therapy, consider the following precautions:

• Blood pressure monitoring: check baseline and periodic readings to avoid hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with existing kidney disease.
• Serum potassium: monitor levels to detect hyperkalemia early.
• Hypersensitivity: discontinue if signs of angioedema or severe rash appear.
• Hepatic impairment: use with caution in patients with moderate to severe liver disease.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil may interact with several drug classes.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium.
• ACE inhibitors (e.g., enalapril): concurrent use raises the likelihood of angioedema and hyperkalemia.
• NSAIDs (e.g., ibuprofen): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment.
• Lithium: olmesartan can increase lithium concentrations, risking toxicity.
• Other antihypertensives (e.g., beta‑blockers): additive hypotensive effect may necessitate closer monitoring.